Cancer. Encouraging results for second-generation antiangiogenesis drugs

Science. 2005 May 27;308(5726):1248-9. doi: 10.1126/science.308.5726.1248.
No abstract available

Publication types

  • News

MeSH terms

  • Angiogenesis Inhibitors / metabolism
  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates / metabolism
  • Benzenesulfonates / pharmacology
  • Benzenesulfonates / therapeutic use*
  • Bevacizumab
  • Clinical Trials as Topic
  • Gastrointestinal Stromal Tumors / blood supply
  • Gastrointestinal Stromal Tumors / drug therapy
  • Humans
  • Kidney Neoplasms / blood supply
  • Kidney Neoplasms / drug therapy
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyridines / metabolism
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Sorafenib
  • United States
  • United States Food and Drug Administration
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Bevacizumab
  • Sorafenib
  • Protein-Tyrosine Kinases